Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07696793

Efficacy and Tolerability of a Simethicone-containing Evacuating Solution for Colorectal Cancer Screening Colonoscopy

Study to evaluate the efficacy and tolerability of a simethicone-containing evacuating solution for colorectal cancer screening colonoscopy.

Recruiting

Interested in participating?

Request Info

Key information

Age range

50 year–69 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Hospital Clínic de Barcelona

Barcelona, 08036, Spain

Location status: Recruiting

Location contact

Maria Pellisé

CONTACT

[email protected]

Maria Pellisé

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women aged 50 to 69.
  • Have participated in the early detection program for colorectal cancer.
  • Positive result in the fecal occult blood test (≥20 μg Hb/g feces).
  • Scheduled screening colonoscopy at Hospital Clínic de Barcelona.
  • Signed informed consent form.

Exclusion criteria

  • Severe renal failure (grade IV or V) (Annex 6, Stages of Renal Impairment) and/or congestive heart failure (New York Heart Association Scale Class III and IV) (Annex 7, NYHA Scale).
  • Colonoscopy within the last year.
  • Barthel Index of <20 (Annex 5, Barthel Index) and who also meet the Rome IV Criteria for the diagnosis of functional constipation (Annex 8, Rome IV Criteria).
  • Mental disability or severe mental disorder (schizophrenia and other psychotic disorders, recurrent severe major depressive disorders, severe obsessive-compulsive disorder, severe personality disorders, and bipolar disorders).
  • Do not understand spoken or written Catalan or Spanish.
  • Partial or total colon resection.
  • Personal history of CRC or colorectal pathology that requires specific follow-up (ulcerative colitis, Crohn's disease, or colorectal adenomas).
  • Terminal illness or serious illness/disability that contraindicates subsequent colon study.
  • Gastrointestinal disorders that contraindicate the use of study products (gastric emptying disorders, gastrointestinal perforation or obstruction, ileus, toxic megacolon).
  • Hypermagnesemia.
  • Rhabdomyolysis.
  • Phenylketonuria.
  • Glucose-6-phosphate dehydrogenase deficiency.
  • Hypersensitivity to the active ingredients of excipients.
  • Pregnancy or breastfeeding.

Treatment and study plan

Clensia®

Drug

Participants will take the treatment in two doses, 4 sachets dissolved in 200cc of water 9-12 hours before the examination and 4 sachets dissolved in 200cc of water 4 hours before the examination.

Citrafleet®

Drug

Participants will take the treatment in two doses, 1 sachet dissolved in 200cc of water 9-12 hours before the examination and 1 sachet dissolved in 200cc of water 4 hours before the examination.

Primary outcomes

  1. Adenoma detection rate

    Time frame: week 2 (Colonoscopy visit)

    Adenoma detection rate, defined as the proportion of patients with at least one adenoma in relation to the total number of subjects in each study group (Clensia® Group (Group A); Citrafleet® Group (Group B)).

Secondary outcomes

  1. Lesion detection rate

    Time frame: week 2 (Colonoscopy visit)

    Lesion detection rate, defined as the proportion of patients with at least one polyp in relation to the total number of subjects in each group.

  2. Adenomas per colonoscopy

    Time frame: week 2 (Colonoscopy visit)

    Adenomas per colonoscopy, defined as the mean number of adenomas detected by colonoscopy in the subjects in each group.

  3. Presence of foam

    Time frame: week 2 (Colonoscopy visit)

    The presence of foam using the CEBuS (Colon Endoscopic Bubble Scale), in which each colonic segment (right colon, transverse colon, left colon) is scored from 0 to 2 (0=no or minimal number of bubbles; 1=moderate amount of bubbles affecting 5-50% of the circumference, affecting the vision of the mucosa and requiring additional time to wash; 2=abundant bubbles occupying >50% of the circumference, obscuring the mucosa and require ring additional time to washing).

  4. Presence of bubbles

    Time frame: week 2 (Colonoscopy visit)

    The presence of bubbles using the CEBuS (Colon Endoscopic Bubble Scale), in which each colonic segment (right colon, transverse colon, left colon) is scored from 0 to 2 (0=no or minimal number of bubbles; 1=moderate amount of bubbles affecting 5-50% of the circumference, affecting the vision of the mucosa and requiring additional time to wash; 2=abundant bubbles occupying >50% of the circumference, obscuring the mucosa and require ring additional time to washing).

  5. Quality of colon cleansing

    Time frame: week 2 (Colonoscopy visit)

    The quality of colon cleansing using the Boston Scale, in which each colonic segment (right colon, transverse colon, and left colon) is scored from 0 to 3 (0=poor, 1=fair, 2=good, 3=excellent). A total score greater than or equal to 6 and greater than or equal to 2 in each segment will be considered adequate.

  6. Need for washing tools during colonoscopy

    Time frame: week 2 (Colonoscopy visit)

    Need for washing tools during colonoscopy. The amount of wash water used during the colonoscopy to complete the test satisfactorily is counted. Likewise, the volume of simethicone used will be counted if it is considered necessary.

  7. Cecal intubation rate

    Time frame: week 2 (Colonoscopy visit)

    Cecal intubation rate. The colonoscopy will be considered complete if the cecum has been reached; otherwise, it will be considered incomplete.

  8. Cecal intubation time

    Time frame: week 2 (Colonoscopy visit)

    Cecal intubation time. Defined as the time elapsed between the introduction of the endoscope and reaching the cecal fundus.

  9. Endoscope removal time

    Time frame: week 2 (Colonoscopy visit)

    Endoscope removal time. Defined as the time elapsed between reaching the cecal fundus and completion of the endoscopy, including the time spent cleaning the colon and excluding endoscopic treatment of lesions.

  10. Requires repeat colonoscopy due to poor preparation

    Time frame: week 2 (Colonoscopy visit)

    Proportion of patients who, after undergoing colonoscopy, require repeat colonoscopy due to poor preparation, defined as a total score of less than 6 or less than 2 in one of the three segments according to the Boston Scale

  11. Adherence to the intake of the preparation

    Time frame: week 2 (Colonoscopy visit)

    Adherence to the intake of the preparation assessed by compliance with the intake in three degrees: completely, more than 50%, less than 50% or not at all (Tolerability and satisfaction questionnaire).

  12. Ease of taking the preparation

    Time frame: week 2 (Colonoscopy visit)

    Ease of taking the preparation assessed with a numerical assessment scale from 0=very difficult to 10=very easy (Tolerability and satisfaction questionnaire).

  13. Palatability of the preparation

    Time frame: week 2 (Colonoscopy visit)

    Palatability of the preparation assessed with a numerical assessment scale from 0=very bad to 10=excellent (Tolerability and satisfaction questionnaire).

  14. Willingness to repeat the intake of the preparation

    Time frame: week 2 (Colonoscopy visit)

    Willingness to repeat the intake of the preparation assessed as yes or no (Tolerability and satisfaction questionnaire).

  15. Overall satisfaction with the intake of the preparation

    Time frame: week 2 (Colonoscopy visit)

    Overall satisfaction with the intake of the preparation assessed with a numerical rating scale from 0=very bad to 10=very good (Tolerability and satisfaction questionnaire).

  16. Endoscopist's satisfaction with the cleaning of faecal remains and bubbles

    Time frame: week 2 (Colonoscopy visit)

    Endoscopist's satisfaction with the cleaning of faecal remains and bubbles, assessed with a numerical assessment scale from 0 = very dissatisfied to 10 = very satisfied (Data collection form).

  17. Rate of adverse events

    Time frame: week 2 (Colonoscopy visit) and week 4 (visit 2)

    Rate of adverse events including symptoms such as nausea, vomiting, abdominal pain, abdominal bloating, headache, chills, dizziness and dry mouth, which will be assessed in the Tolerability and Satisfaction Questionnaire (Tolerability and Satisfaction Questionnaire).

Study contacts

Contact information is provided by the study sponsor or research team.

Judit Pich

CONTACT

[email protected]

+34 932275400 ext. 2815

Maria Pellisé

CONTACT

[email protected]

+34 932275400

Sponsors and collaborators

Lead sponsor

Fundacion Clinic per a la Recerca Biomédica

Other

Registry information

Official study title

Efficacy and Tolerability of a Simethicone-containing Evacuating Solution for Colorectal Cancer Screening Colonoscopy: a Randomized Parallel Comparative Trial CLEAN+

Acronym: CLEAN+

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jul 10, 2026
Registry last updated
Jul 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.